02/04/2024
Milan, April 2, 2024 — Tethis S.p.A., a pioneer in the development of an innovative platform for liquid biopsy testing, is pleased to announce the enrollment of the first two patients in the clinical study TET-22-001. This study, titled “Feasibility evaluation of See.d pre-analytical platform performance: from whole blood to plasma and SmartBioSurface ® slides for liquid biopsy applications”, is being conducted at the European Institute of Oncology in Milan, Italy.